common.study.topics.clinical

Treatment of Moderate to Severe Lateral Canthal Lines

common.study.values.description

Treatment of Moderate to Severe Lateral Canthal Lines

The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe LCL.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

No pharmaceutical medication involved common.study.methods.has-drugs-no
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Biological - botulinum toxin

neuromodulator

Biological - Placebo

placebo

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines

common.study.values.clinical-trial-id

NCT04249687

participant.views.study.view.id

dR6Z0d